Bill > SB5204

This bill seeks to authorize and fund a research study at the University of Washington examining ibogaine-assisted therapy as a potential treatment for opioid use disorder (OUD). The bill first provides context about ibogaine, a naturally occurring psychoactive substance from the Tabernanthe iboga plant traditionally used in African spiritual ceremonies, which has shown promise in rapidly reducing opioid withdrawal symptoms and cravings. Recognizing the ongoing public health crisis of OUD and limitations of current treatments like methadone and buprenorphine, the bill proposes a three-year prospective, randomized cohort study conducted at a licensed clinic in Mexico. The study will evaluate ibogaine-assisted therapy's effectiveness by measuring outcomes such as treatment engagement, opioid use reduction, mortality, functional status, craving levels, motivation to change, and self-efficacy. By using rigorous research techniques including toxicology and standard assessment scales, the study aims to generate critical scientific evidence about ibogaine's potential as an innovative treatment option for individuals who have not responded to existing OUD therapies, potentially paving the way for future larger trials and more effective interventions.

Health and Social Services

https://app.leg.wa.gov/billsummary?BillNumber=5204&Year=2025&Initiative=false